EMPIRICAL FOLLOW-UP CRITIQUES OF STATIN DRUGS THROUGH OPTIMIZED COQ10 AND NIACIN DOSE COMBINATION TO OVERCOME GENETIC MUTATION OF CYTOCHROME P450 (CYP) 3A4

INTRODUCTION: This work encompasses follow-up techniques to statin with coenzymes Q10 and Niacin so as to reduce the doses and frequency of Statin drugs. The genes synthesizing cytochrome P450 enzymes (CYP2D6, CYP3A4, and CYP3A5), a mitochondrial enzyme (GATM), an inflow transporter (SLCO1B1), and efflux transporters, which are all linked to elevated statin muscle concentrations (ABCB1 and ABCG2) lead to dangerous consequence of rhabdomyolysis. The CoQ10 and Niacin (Vitamin) is a rational bio-component, the follow-up therapy aid to terminate statin therapy. METHODOLOGY: The recommended 16 patients with all valid medical documentation were selected as per the criteria, those were already in the Statin treatment in a multi-specialty hospital. All physiological, Biochemistry, Pathological reports were assembled before entering to intervene therapy. Thereafter, the targeted drugs of CoQ10 & Niacin were administered to all patients individually as well as with combination. Both the groups administered doses for 15-30 days and resting time of 5-6 days respectively. RESULT: Data extracted from both (before & after the intervention) the therapy were comparatively analyzed by statistical tools, taking consideration of Correlation Regression values, Pearson's & Spearman's Correlation. The values are comparatively evaluated from Lipid Profiles of both therapies. All around the P-Value is < .00001. The result is significant at p < .05. ANOVA study between both the therapies was taken in contrast to evaluate the Triglyceride of LP which is a very essential parameter to analyze the Treatment variance. The f-ratio value is 2.25749. The p-value is 0.143424. The result is not significant at p < 0.05. A range difference in the triglyceride levels signifies the effectiveness of the treatment. CONCLUSION: Thus, slowly withdrawals of Statins dependency could be possible either by reducing the dose or replacing the total stains drug molecule from treatment profile which would work positively on max. Probability score.